Diabetes InsipidusMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

570 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp37

Immediate Priorities

›Hemodynamic and neurologic threats from severe hypernatremia

›Serum sodium >160 mmol/L — seizure and coma risk

›Immediate IV access and fluid resuscitation

›Continuous cardiac monitoring

›Altered mental status — lethargy, confusion, coma

›GCS assessment with serial re-evaluation

›If GCS <13, escalate to resuscitation bay

›Hemodynamic instability from massive free water loss

›SBP <90 mmHg — initiate IV crystalloid

›MAP target >65 mmHg

›Inability to access water — intubated, postoperative, impaired consciousness

›Extreme dehydration risk without compensatory polydipsia

›Initiate IV hypotonic fluid immediately

Stabilization Targets

›Sodium correction rate — non-negotiable safety limit

›Correct hypernatremia at ≤10–12 mmol/L per 24 hours

›Faster correction risks cerebral edema

›Serial sodium every 2–4 hours during active correction

›Free water deficit calculation

›Free water deficit (L) = 0.6 x weight (kg) x [(Na/140) - 1]

›Replace deficit over 48–72 hours in severe cases

›IV fluid of choice — D5W for free water replacement

›0.45% NaCl acceptable if mild volume depletion also present

›Avoid isotonic saline — will worsen hypernatremia

Escalation and Consults

›Escalation triggers requiring ICU or step-down admission

›Persistent altered mental status despite correction

02History/hx52

Core Symptoms

›Polyuria characteristics

›Urine output typically >3 L/day in adults (>30 mL/kg/day)

›Can exceed 8–10 L/day in complete DI

›Nocturia — often the most disruptive symptom

›Urine appearance consistently pale, dilute

›Polydipsia characteristics

›Intense, unrelenting thirst

›Preference for cold water — classic feature of central DI

›Nighttime fluid intake and nocturnal awakenings

›Inability to quench thirst despite large volumes consumed

Onset and Timing

›Onset pattern as diagnostic clue

›Abrupt onset — favors central DI, especially post-surgical or post-traumatic

›Post-pituitary surgery DI typically appears within 24–48 hours

›Triphasic pattern possible: DI → SIADH → permanent DI

›Gradual onset — may suggest nephrogenic DI or primary polydipsia

›Drug-induced nephrogenic DI (lithium) often months to years of exposure

›Pregnancy onset — 2nd/3rd trimester, due to increased placental vasopressinase

›Gestational DI typically resolves postpartum

Triggers and Exposures

›Precipitating events

›Recent head trauma — especially basilar skull fracture

›Neurosurgery or pituitary surgery

›Transsphenoidal surgery: DI in ~10.7% of cases (4.5% permanent)

›Craniopharyngioma resection highest risk: 46.3% post-surgical DI

›New medications — lithium most common drug cause

›~10% of long-term lithium users affected

03Physical Exam/exam36

Vital Signs and Hemodynamic Assessment

›Vital sign patterns in DI

›Tachycardia — compensatory response to dehydration

›Heart rate >100 bpm warrants fluid assessment

›Orthostatic hypotension — SBP drop >20 mmHg or DBP drop >10 mmHg on standing

›Indicates significant intravascular volume depletion

›Weight — serial measurements for free water tracking

›Acute weight loss reflects free water deficit

Hydration Status

›Dehydration findings

›Dry mucous membranes

›Assess buccal mucosa and tongue

›Decreased skin turgor

›Note: may be preserved in hypernatremic dehydration due to intracellular fluid shifts

›Sunken eyes and sunken fontanelle in infants

›Urine output monitoring

›Dilute, pale, high-volume urine output on direct observation

Neurologic Examination

›Mental status and CNS findings

›Level of consciousness — GCS scoring

›Lethargy → confusion → stupor → coma with progressive hypernatremia

›Seizure activity

›Hypernatremia Na >160 mmol/L — seizure threshold lowered

›Visual field testing

›Bitemporal hemianopia — sellar mass compressing optic chiasm

›Fundoscopic exam

›Papilledema — mass effect or raised intracranial pressure

04Differential Diagnosis/ddx33

Life-Threatening Causes of Polyuria

›Central DI (AVP deficiency) — ICD-10: E23.2

›Deficient AVP secretion from hypothalamus or posterior pituitary

›Abrupt onset, dilute polyuria, preference for cold water

›Post-surgical most common acquired cause

›Associated hypernatremia if thirst impaired or access restricted

›Nephrogenic DI (AVP resistance) — ICD-10: N25.1

›Renal tubular insensitivity to AVP

›Drug-induced (lithium) most common acquired form

›Partial response to desmopressin distinguishes from central DI

Polyuria Mimics

›Primary polydipsia (psychogenic polydipsia) — ICD-10: F50.89

›Excessive fluid intake despite normal AVP

›More common in psychiatric patients or health-conscious individuals

›Urine can concentrate with water deprivation (distinguishes from DI)

›Gradual onset, fluctuating symptoms, less nocturia

›Diabetes mellitus — osmotic diuresis from glucosuria — ICD-10: E11.65

›Urine glucose positive on dipstick

›Serum glucose >11.1 mmol/L confirms

›Osmotic diuresis from other solutes

›Mannitol, urea, post-obstructive diuresis, high-protein tube feeds

›Urine osmolality elevated (>300 mOsm/kg) unlike DI

›Chronic kidney disease — ICD-10: N18.9

›Impaired concentrating ability with elevated creatinine

›Hypercalcemia-induced nephrogenic DI — ICD-10: E83.52

›Serum calcium >2.6 mmol/L causing tubular dysfunction

›Hypokalemia-induced nephrogenic DI — ICD-10: E87.6

›Serum potassium <3.0 mmol/L causing renal concentrating defect

05Laboratory Tests/lt40

Essential Initial Labs

›Serum sodium and osmolality — diagnostic cornerstone

›Na >145 mmol/L reliably confirms AVP deficiency

›Na <135 mmol/L essentially rules out DI

›Serum osmolality >295 mOsm/kg with dilute urine = diagnostic of DI

›Simultaneous serum and urine osmolality mandatory for interpretation

›Urine osmolality and specific gravity

›DI: urine osmolality <300 mOsm/kg, specific gravity <1.005

›In complete DI, urine osmolality may be as low as 50–100 mOsm/kg

›Diagnostic hallmark: high serum osmolality with inappropriately dilute urine

›Serum glucose

›Rule out osmotic diuresis from diabetes mellitus

›Normal glucose excludes glucosuria as cause of polyuria

›Serum calcium and potassium

›Hypercalcemia (>2.6 mmol/L) and hypokalemia (<3.0 mmol/L) cause nephrogenic DI

›Correct electrolyte disorder may resolve nephrogenic DI

›BUN and creatinine

›Renal function baseline and desmopressin clearance assessment

›Desmopressin contraindicated with CrCl <50 mL/min

›Serum electrolytes panel — sodium, potassium, chloride, bicarbonate

Advanced Diagnostic Labs

›Plasma copeptin — AVP surrogate marker

›Basal copeptin >21.4 pmol/L → nephrogenic DI (AVP resistance)

›Sensitivity 94%, specificity 96% for nephrogenic DI

›Copeptin >5.6 pmol/L after osmotic stimulation → rules out central DI

›Copeptin-based approach being adopted to replace water deprivation test (NEJM 2018, 2023)

›Hypertonic saline-stimulated copeptin >6.5 pmol/L — rules out central DI (95% accuracy, NEJM 2023)

›Arginine-stimulated copeptin >3.8 pmol/L — rules out central DI (sensitivity 93%, Lancet 2019)

06Diagnostic Tests/dt58

Scoring Systems

›Novel AVP-D diagnostic score (Lancet Diabetes Endocrinol 2025)

›Uses basal laboratory and clinical parameters to diagnose central DI vs. primary polydipsia

›Parameters include serum sodium, urine osmolality, clinical features

›Validated in two international multicentre prospective diagnostic studies

›High diagnostic accuracy without requiring water deprivation or stimulation test

›Score interpretation guides further testing and treatment initiation

›Water deprivation test — classic approach being supplanted by copeptin

›8-hour fluid deprivation followed by desmopressin 2 mcg IM

›Measure plasma and urine osmolality hourly for 4 hours post-DDAVP

›Central DI: urine concentrates >800 mOsm/kg after DDAVP

›Nephrogenic DI: urine remains dilute despite DDAVP

›Primary polydipsia: urine concentrates with deprivation alone (>800 mOsm/kg)

›Limitations: prolonged duration, risk of severe hypernatremia, up to 30% misclassification

›Contraindicated in patients with Na >150 mmol/L at baseline

MRI

›MRI pituitary and hypothalamus — first-line imaging for all new central DI

›Protocol: with and without gadolinium contrast

›T1-weighted sequences — assess posterior pituitary bright spot

›T2-weighted sequences — stalk thickening and inflammatory changes

›Coronal and sagittal planes through sella and suprasellar region

›Loss of posterior pituitary bright spot (T1 hyperintensity)

›Characteristic finding in central DI — absent in ~95% of central DI cases

›Normally visible as hyperintense signal in posterior pituitary on T1

›Pituitary stalk thickening >3 mm

›Suggests inflammatory, infiltrative, or neoplastic process

›Differential: lymphocytic hypophysitis, sarcoidosis, IgG4-related disease, germinoma, Langerhans cell histiocytosis

›Mass lesions identified on MRI

07Disposition/dispo28

Admission Indications

›Inpatient admission criteria

›Severe hypernatremia — Na >155 mmol/L or any symptomatic hypernatremia

›Requires controlled IV correction with serial monitoring

›Altered mental status from dehydration or hypernatremia

›Inability to maintain oral hydration — vomiting, impaired consciousness

›New-onset DI requiring workup for underlying mass lesion

›MRI pituitary and endocrinology consult

›Post-surgical DI requiring close sodium and fluid monitoring

›Triphasic response surveillance in pituitary surgery patients

›Adipsic DI — requires inpatient establishment of fluid and desmopressin regimen

›Hemodynamic instability from free water loss

ICU Admission Criteria

›ICU-level care indications

›Sodium >165 mmol/L with neurologic compromise

›Continuous sodium monitoring every 1–2 hours

›Invasive monitoring if hemodynamically unstable

›Seizure from hypernatremia

›Coma or GCS <10

›Post-surgical with diabetes insipidus plus concurrent SIADH risk (triphasic)

Discharge Criteria

›Safe discharge criteria

›Stable serum sodium in normal or near-normal range

›Adequate oral intake — able to drink to thirst

›Established desmopressin dose and patient educated on use

›Follow-up confirmed within 1–2 weeks for sodium recheck

Specialist Consultation

›Consultation pathways

08Treatment/t68

Acute Severe Hypernatremia

›IV free water replacement — cornerstone of acute management

›D5W (5% dextrose in water) — primary agent for free water replacement

›Preferred when patient cannot drink

›Rate guided by free water deficit and target correction rate

›Free water deficit calculation

›Deficit (L) = 0.6 x weight (kg) x [(measured Na / 140) - 1]

›Use 0.5 as coefficient in elderly females

›Replace deficit over 48–72 hours in severe cases

›Rate of sodium correction — safety limit ≤10–12 mmol/L per 24 hours

›Maximum 2 mmol/L per hour in first 1–2 hours if seizure or coma present

›Slower thereafter to avoid cerebral edema

›Ensure unrestricted access to oral water if patient can drink

›Oral rehydration preferred when safe — faster and physiologic

Desmopressin — Central DI Treatment

›Desmopressin (DDAVP) — first-line treatment for central DI

›Acute/parenteral — inpatient or perioperative setting

›IV or SC desmopressin 1–4 mcg every 8–24 hours

›Onset of action 1–3 hours; duration 6–24 hours

›Titrate dose to urine output and serum sodium response

›Intranasal desmopressin 10–40 mcg/day — split into 1–3 doses

›Absorption variable; avoid during nasal congestion

›Chronic oral maintenance

›Start 0.05 mg orally twice daily

›Titrate to 0.1–0.8 mg/day in divided doses (range up to 1.2 mg/day)

›Congenital DI may require higher doses (median ~600 mcg/day vs. 200 mcg acquired)

›Desmopressin escape technique — skip a dose 1–2 times per week

›Allows breakthrough aquaresis to prevent dilutional hyponatremia

›Reduces cumulative free water retention

›Monitoring on desmopressin

›Serum sodium — every 1–3 months once stable; more frequent during titration

›24-hour urine volume target <2–3 L/day

›Contraindications and cautions

›Ineffective in nephrogenic DI — do not use

›Contraindicated with CrCl <50 mL/min

›Major adverse effect: dilutional hyponatremia — life-threatening if fluid intake not managed

Nephrogenic DI Treatment

›Remove offending agent — first and essential step

›Lithium discontinuation — may be only partially reversible after prolonged use

›Lithium-induced NDI persisting after discontinuation is managed pharmacologically

›Discontinue demeclocycline, foscarnet, or other causative agents

›Thiazide diuretics — paradoxical antidiuretic effect

›Hydrochlorothiazide 25–50 mg/day orally

›Mechanism: volume contraction → proximal tubule reabsorption → less urine reaching collecting duct

›Reduces urine volume by ~50% in nephrogenic DI

›Amiloride 5–10 mg/day orally — especially for lithium-induced NDI

›Blocks ENaC channel — reduces lithium entry into principal cells

›Combine with hydrochlorothiazide for additive effect

›NSAIDs — adjunct for severe nephrogenic DI

›Indomethacin 25–50 mg three times daily orally

›Mechanism: reduce prostaglandin-mediated antagonism of AVP

›Use in severe cases; monitor renal function and GI side effects

›Low-sodium low-protein diet as adjunct

›Sodium <2 g/day — reduces solute load and obligate urine output

›Low-protein diet reduces renal solute load and urine volume

Electrolyte Correction

›Address reversible causes of nephrogenic DI

›Hypercalcemia — serum calcium >2.6 mmol/L

›IV saline hydration; bisphosphonates for hypercalcemia of malignancy

›Treat underlying cause to restore renal concentrating ability

›Hypokalemia — serum potassium <3.0 mmol/L

›IV or oral potassium replacement targeting >3.5 mmol/L

›Correction may restore nephrogenic DI from hypokalemia

Intercurrent Illness Management

›DI management during acute illness

›Vomiting or diarrhea preventing oral intake

›IV hypotonic fluids (D5W or 0.45% NaCl) to replace free water

›Consider holding desmopressin if hyponatremia risk elevated

›Fever — increases insensible losses, escalates free water needs

›Increase fluid intake; closely monitor sodium

›Surgical patients with DI

›IV desmopressin perioperatively

›Hourly urine output and sodium monitoring

09Special Populations/sp53

Pregnancy

›Gestational DI — unique mechanism and management

›Placental vasopressinase degrades natural AVP — onset 2nd/3rd trimester

›Prevalence approximately 1 in 30,000 pregnancies

›Typically resolves within days to weeks postpartum

›Transient DI may unmask pre-existing subclinical central DI

›Severity increases with each pregnancy in some cases

›Treatment in pregnancy

›Desmopressin is the treatment of choice — resistant to placental vasopressinase

›Does not cause uterine contractions (no V1a receptor activity)

›Safe in pregnancy — extensive clinical use data

›Thiazides and NSAIDs — avoid in pregnancy (fetal harm risk)

›Monitoring in pregnancy

›Serum sodium every 2–4 weeks

›Dose adjustment often required as vasopressinase levels fluctuate

›Breastfeeding — desmopressin safe; minimal transfer into breast milk

›Pre-existing central DI — desmopressin dose may need to increase in pregnancy

Geriatric

›Older adults — increased vulnerability and modified management

›Reduced thirst perception (adipsia physiology)

›Greater risk of severe hypernatremia without compensatory polydipsia

›Scheduled fluid intake protocols required in care facility patients

›Altered pharmacokinetics

›Reduced renal clearance — lower desmopressin doses required

›CrCl <50 mL/min contraindicates desmopressin

›Hyponatremia risk from desmopressin higher in elderly

›Lower baseline free water excretion

›More frequent sodium monitoring — every 2–4 weeks after initiation

10Background/b66

Epidemiology

›Prevalence and incidence data

›DI prevalence — approximately 1 in 25,000 persons

›Rare disorder; all subtypes combined

›Central DI (AVP deficiency) — most common type in adults

›Acquired causes predominate (post-surgical, post-traumatic, infiltrative)

›Idiopathic central DI: 30–50% of cases; thought to be autoimmune

›Familial central DI: ~1% of cases (AVP gene mutations)

›Nephrogenic DI — drug-induced accounts for majority of acquired cases

›Lithium: affects ~10% of long-term users

›Congenital nephrogenic DI: >280 disease-causing mutations in AVPR2 and AQP2 genes

›Post-pituitary surgery DI

›Occurs in ~10.7% of transsphenoidal surgeries (4.5% permanent)

›Craniopharyngioma resection: 46.3% post-surgical DI rate

›Gestational DI — approximately 1 in 30,000 pregnancies

›Mortality and morbidity

›Untreated or unrecognized DI — severe morbidity from hypernatremic encephalopathy

›Osmotic demyelination syndrome from rapid-onset hypernatremia

›Intellectual disability in children with recurrent hypernatremia

›Adipsic DI — highest mortality due to absent thirst mechanism

Pathophysiology

›AVP deficiency (central DI) mechanism

›AVP (arginine vasopressin / antidiuretic hormone) synthesized in hypothalamic supraoptic and paraventricular nuclei

›Transported to posterior pituitary for storage and release

›Released in response to increased plasma osmolality (osmoreceptors) or hypotension/hypovolemia (baroreceptors)

›AVP acts on V2 receptors in renal collecting duct principal cells

›Activates adenylyl cyclase → cAMP → protein kinase A → aquaporin-2 (AQP2) insertion

›AQP2 water channels allow free water reabsorption from collecting duct

›Absent or deficient AVP → no AQP2 insertion → massive dilute urine output

›New nomenclature: central DI renamed AVP deficiency (AVP-D); nephrogenic DI renamed AVP resistance (AVP-R)

›AVP resistance (nephrogenic DI) mechanism

›Normal AVP secretion but renal insensitivity

›Genetic: AVPR2 mutation (V2 receptor) or AQP2 mutation

›Acquired: lithium accumulates in collecting duct cells via ENaC

›Reduces AQP2 expression and function

›May be partially irreversible after long-term lithium exposure

›Hypercalcemia — calcium reduces V2 receptor signaling

›Hypokalemia — reduces AQP2 channel expression

›Compensatory polydipsia

›Intact thirst mechanism protects against hypernatremia

›Osmoreceptors in hypothalamus trigger thirst at plasma osmolality >285 mOsm/kg

›Adipsic DI — thirst mechanism destroyed (hypothalamic damage)

›Most dangerous variant; sodium can rise precipitously

›Triphasic response after pituitary surgery

›Phase 1 (days 1–3): DI from AVP release failure

›Phase 2 (days 4–7): SIADH from uncontrolled AVP release from dying neurons

›Phase 3 (>day 10): permanent DI if pituitary stalk irreversibly damaged

Therapeutic Considerations

›Treatment selection by DI subtype

›Central DI — desmopressin first-line; effective in complete and partial central DI

›Desmopressin: synthetic AVP analogue; V2 receptor selectivity; no V1a (pressor) activity

›Oral preferred for outpatient; IV/SC for inpatient or perioperative

›Nephrogenic DI — desmopressin ineffective; thiazide + amiloride first-line

›Paradoxical antidiuresis via volume contraction reduces GFR → increased proximal reabsorption → less water reaching collecting duct

›Amiloride blocks ENaC — preferred for lithium-induced NDI

›Copeptin as biomarker — replacing water deprivation test

›Hypertonic saline-stimulated or arginine-stimulated copeptin — diagnostic accuracy >93–95%

›NEJM 2018 (Fenske et al.) and NEJM 2023 (Refardt et al.) established copeptin protocols

›Desmopressin escape protocol — prevents dilutional hyponatremia

›Delay one dose per week to allow breakthrough aquaresis

›Reduces cumulative free water overload in long-term use

›Monitoring targets on treatment

›Urine output <2–3 L/day

›Serum sodium within normal range 135–145 mmol/L

›Desmopressin titrated to lowest effective dose

›Expected recovery trajectories

›Post-surgical central DI: resolves in days to weeks in ~60% of cases

›Drug-induced nephrogenic DI: may partially reverse after drug discontinuation

›Lithium-induced NDI: partial recovery likely; complete recovery less common after years of use

11Patient Discharge Instructions/pdi31

copy discharge instructions

›What is Diabetes Insipidus?

›A condition where your body loses too much water through excessive urination

›Caused by either a hormone deficiency (central DI) or the kidneys not responding to the hormone (nephrogenic DI)

›Different from diabetes mellitus — it is not related to blood sugar

›Your medications

›If prescribed desmopressin (DDAVP)

›Take exactly as instructed — do not take extra doses without medical advice

›Do not drink more water than necessary — this can cause dangerous low sodium levels

›Your doctor may ask you to skip a dose once a week — this is intentional and helps prevent low sodium

›If prescribed water pills (hydrochlorothiazide) or amiloride

›Take as directed; do not stop without asking your doctor

›Monitor for dizziness or light-headedness (low blood pressure effect)

›Hydration and diet

›Drink water when thirsty — do not restrict water intake

›If you do not feel thirsty, follow your doctor's recommended fluid schedule

›Low-salt and low-protein diet may help if you have nephrogenic DI

›Always carry water with you

›Wear a medical alert bracelet or carry identification stating your diagnosis and medications

›Warning signs — Return to the emergency room immediately if you experience

›Decreased urination with headache, nausea, or confusion (may mean low sodium from desmopressin overtreatment)

›Severe thirst with decreasing consciousness or confusion

›Inability to keep up with fluid intake due to vomiting or illness

›Seizures or loss of consciousness

›New headache, visual changes, or sudden neurologic symptoms

›Follow-up instructions

›Blood sodium check within 1–2 weeks of discharge or starting/changing desmopressin

›Endocrinology appointment for ongoing management and MRI if needed

12References/r68

Guidelines and Key Sources

›Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ

›Diagnosis and Management of Central Diabetes Insipidus in Adults

›Journal of Clinical Endocrinology and Metabolism 2022

›PMID 35771962

›Flynn K, Hatfield J, Brown K, Vietor N, Hoang T

›Central and Nephrogenic Diabetes Insipidus: Updates on Diagnosis and Management

›Frontiers in Endocrinology 2024

›PMID 39845881

›Newell-Price J, Drummond JB, Gurnell M, et al

›Approach to the Patient With Suspected Hypotonic Polyuria

›Journal of Clinical Endocrinology and Metabolism 2025

›PMID 39148427

›Atila C, Refardt J, Christ-Crain M

›Arginine Vasopressin Deficiency: Diagnosis, Management and the Relevance of Oxytocin Deficiency

›Nature Reviews Endocrinology 2024

›PMID 38693275

›Fenske W, Refardt J, Chifu I, et al

›A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus

›New England Journal of Medicine 2018

›NEJM 2018; 379:428-439

›Refardt J, Atila C, Chifu I, et al

›Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency

›New England Journal of Medicine 2023

›NEJM 2023 published online

›Winzeler B, Cesana-Nigro N, Refardt J, et al

›Arginine-Stimulated Copeptin Measurements in the Differential Diagnosis of Diabetes Insipidus

›Lancet 2019

Learn More: Diabetes Insipidus→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.